Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026)

Vera Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 60.56% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 5106.0% year-over-year to 60.56%; the trailing twelve-month figure through Mar 2026 stood at 60.56% (down 5106.0% YoY), and the FY2025 full-year result was 49.16%, down 4097.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 60.56%, down from 55.09% in the prior quarter.
• The five-year high for Return on Capital Employed was 6.56% in Q4 2024, with the low at 60.56% in Q1 2026.
• Historically, Return on Capital Employed has averaged 26.66% across 5 years, with a median of 22.41% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed surged 6547 bps — and 2026, when it plunged 5106 bps.
• Vera Therapeutics' Return on Capital Employed stood at 17.68% in 2022, then grew by 26 bps to 13.15% in 2023, then soared by 50 bps to 6.56% in 2024, then plunged by 739 bps to 55.09% in 2025, then retreated by 10 bps to 60.56% in 2026.
• The last three Return on Capital Employed figures came in at 60.56% (Q1 2026), 55.09% (Q4 2025), and 26.67% (Q3 2025), per Business Quant data.